BB
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP · Investor
1Y performance ⓘ
+53%
AUM (13F)
$17.4B
# of Holdings
84
3Y performance ⓘ
+92%
vs S&P 500 ⓘ
+14%
Updated
Mar 31
BAKER BROS. ADVISORS LP's BAKER BROS. ADVISORS LP holds 84 U.S.-equity positions worth $17.4B (SEC 13F, Q1 2026). Top positions: Incyte Genomics Inc 16.6%, Beone Medicines Ltd. 15.0%, Insmed, Inc. 7.0%. 13F-replication return is +92% over 3 years (+14 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| INCY Incyte Genomics Inc | 16.6% | 30.7M | $2.9B | — | $72.27 | $120.13 (+66%) | 2026-03-31 |
| ONC Beone Medicines Ltd. | 15.0% | 8.8M | $2.6B | — | $272.17 | $367.98 (+35%) | 2026-03-31 |
| INSM Insmed, Inc. | 7.0% | 7.4M | $1.2B | ▲ 13% (+828K) | $85.96 | $115.23 (+34%) | 2026-03-31 |
| MDGL Madrigal Pharmaceuticals, Inc. Common Stock | 6.4% | 2.1M | $1.1B | — | $256.97 | $505.58 (+97%) | 2026-03-31 |
| ACAD Acadia Pharmaceuticals Inc. | 5.5% | 42.9M | $955M | — | $18.93 | $20.02 (+6%) | 2026-03-31 |
| RVMD Revolution Medicines, Inc. Common Stock | 5.3% | 9.6M | $929M | ▲ 1.1% (+100K) | $30.30 | $207.73 (+586%) | 2026-03-31 |
| CELC Celcuity Inc. Common Stock | 5.2% | 7.9M | $904M | — | $24.80 | $78.75 (+217%) | 2026-03-31 |
| KOD Kodiak Sciences Inc Common Stock | 4.4% | 19.9M | $759M | — | $9.05 | $101.98 (+1027%) | 2026-03-31 |
| KYMR Kymera Therapeutics, Inc. Common Stock | 4.1% | 8.7M | $721M | — | $39.43 | $113.05 (+187%) | 2026-03-31 |
| SMMT Summit Therapeutics Inc. Common Stock | 4.0% | 36.4M | $690M | — | $11.90 | $16.84 (+42%) | 2026-03-31 |
| PRAX Praxis Precision Medicines, Inc. Common Stock | 3.2% | 1.8M | $565M | ▲ 56% (+627K) | $208.46 | $288.87 (+39%) | 2026-03-31 |
| RYTM Rhythm Pharmaceuticals, Inc. Common Stock | 2.8% | 5.6M | $487M | — | $17.99 | $96.00 (+433%) | 2026-03-31 |
| ALKS Alkermes Inc. plc | 2.0% | 10.0M | $354M | — | $26.97 | $40.85 (+51%) | 2026-03-31 |
| GRAL GRAIL, Inc. Common Stock | 1.2% | 4.0M | $208M | ▲ 93% (+1.9M) | $41.82 | $138.69 (+232%) | 2026-03-31 |
| EWTX Edgewise Therapeutics, Inc. Common Stock | 1.2% | 6.6M | $207M | — | $14.00 | $40.65 (+190%) | 2026-03-31 |
| IONS Ionis Pharmaceuticals, Inc. Common Stock | 0.9% | 2.0M | $154M | ▲ 14% (+256K) | $70.05 | $45.57 (−35%) | 2026-03-31 |
| KNSA Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares | 0.8% | 2.8M | $136M | — | $18.70 | $74.47 (+298%) | 2026-03-31 |
| IMVT Immunovant, Inc. Common Stock | 0.8% | 5.5M | $136M | — | $21.09 | $34.30 (+63%) | 2026-03-31 |
| ROIV Roivant Sciences Ltd. Common Shares | 0.8% | 4.9M | $135M | ▼ 12% (−687K) | $13.74 | $36.58 (+166%) | 2026-03-31 |
| IDYA IDEAYA Biosciences, Inc. Common Stock | 0.8% | 3.9M | $131M | ▲ 9.1% (+328K) | $23.64 | $38.36 (+62%) | 2026-03-31 |
| ARWR Arrowhead Research Corporation | 0.7% | 2.0M | $125M | ▼ 8.4% (−183K) | $33.82 | $65.63 (+94%) | 2026-03-31 |
| STOK Stoke Therapeutics, Inc. Common Stock | 0.6% | 3.3M | $109M | — | $10.74 | $26.20 (+144%) | 2026-03-31 |
| IMTX Immatics N.V. Ordinary Shares | 0.6% | 10.9M | $107M | ▼ 9.7% (−1.2M) | $7.22 | $8.78 (+22%) | 2026-03-31 |
| ABCL AbCellera Biologics Inc. Common Shares | 0.6% | 30.3M | $106M | ▲ 10.0% (+2.8M) | $5.95 | $14.63 (+146%) | 2026-03-31 |
| ABVX Abivax S.a. | 0.6% | 876K | $98M | — | $84.90 | $97.06 (+14%) | 2026-03-31 |
| CRNX Crinetics Pharmaceuticals, Inc. | 0.5% | 2.4M | $85M | ▲ 43% (+703K) | $42.08 | — (−14%) | 2026-03-31 |
| REPL Replimune Group, Inc. | 0.5% | 11.0M | $84M | — | $12.51 | $13.39 (+7%) | 2026-03-31 |
| CELC 2.75 08/01/31 Celcuity Inc. | 0.4% | 30.8M | $75M | — | $1.33 | — (+83%) | 2026-03-31 |
| NRIX Nurix Therapeutics, Inc. Common stock | 0.4% | 4.7M | $72M | — | $10.56 | $23.77 (+125%) | 2026-03-31 |
| DNLI Denali Therapeutics Inc. Common Stock | 0.4% | 3.7M | $72M | — | $22.24 | $20.62 (−7%) | 2026-03-31 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | 0.4% | 852K | $72M | ▲ 7.9% (+62K) | $23.41 | $89.47 (+282%) | 2026-03-31 |
| GLUE Monte Rosa Therapeutics, Inc. Common Stock | 0.4% | 4.3M | $71M | — | $6.13 | $11.46 (+87%) | 2026-03-31 |
| GPCR Structure Therapeutics Inc. | 0.4% | 1.4M | $69M | — | $22.23 | $30.73 (+38%) | 2026-03-31 |
| TRDA Entrada Therapeutics, Inc. Common Stock | 0.4% | 5.1M | $64M | — | $14.33 | $6.26 (−56%) | 2026-03-31 |
| BCYC Bicycle Therapeutics Plc | 0.3% | 10.9M | $51M | — | $20.63 | $3.67 (−82%) | 2026-03-31 |
| SYRE Spyre Therapeutics, Inc. Common Stock | 0.3% | 1.0M | $50M | — | $15.64 | $90.56 (+479%) | 2026-03-31 |
| RAPP Rapport Therapeutics, Inc. Common Stock | 0.3% | 1.5M | $48M | — | $23.18 | $34.27 (+48%) | 2026-03-31 |
| ALMS Alumis Inc. Common Stock | 0.2% | 2.0M | $44M | ▲ 29% (+450K) | $15.25 | $7.43 (−51%) | 2026-03-31 |
| MIRM Mirum Pharmaceuticals, Inc. Common Stock | 0.2% | 446K | $41M | NEW (+446K) | $66.42 | $86.09 (+30%) | 2026-03-31 |
| VRDN Viridian Therapeutics, Inc. Common Stock | 0.2% | 2.0M | $39M | — | $15.96 | $20.07 (+26%) | 2026-03-31 |
| ELVN Enliven Therapeutics, Inc. Common Stock | 0.2% | 905K | $35M | ▲ 234% (+634K) | $32.34 | $46.06 (+42%) | 2026-03-31 |
| PRLD Prelude Therapeutics Incorporated | 0.2% | 10.1M | $35M | — | $5.70 | $3.83 (−33%) | 2026-03-31 |
| DBVT DBV Technologies S.A. | 0.2% | 1.5M | $31M | — | $3.09 | $11.50 (+272%) | 2026-03-31 |
| DSGN Design Therapeutics, Inc. Common Stock | 0.2% | 2.6M | $28M | ▲ 16% (+353K) | $5.72 | $12.82 (+124%) | 2026-03-31 |
| CNTA Centessa Pharmaceuticals Plc | 0.1% | 671K | $27M | — | $12.88 | — (+209%) | 2026-03-31 |
| CTMX CytomX Therapeutics, Inc. | 0.1% | 5.0M | $23M | ▲ 17% (+725K) | $2.77 | $2.75 (−1%) | 2026-03-31 |
| JBIO Jade Biosciences, Inc. Common Stock | 0.1% | 1.6M | $23M | — | $15.43 | $14.10 (−9%) | 2026-03-31 |
| IRON Disc Medicine, Inc. Common Stock | 0.1% | 350K | $22M | ▲ 3.7% (+13K) | $55.66 | $65.40 (+18%) | 2026-03-31 |
| IMCR Immunocore Holdings Plc | 0.1% | 734K | $22M | ▼ 68% (−1.6M) | $42.57 | $30.27 (−29%) | 2026-03-31 |
| XENE Xenon Pharmaceuticals Inc | 0.1% | 370K | $22M | — | $37.86 | $39.62 (+5%) | 2026-03-31 |
Showing top 50 of 84 holdings by value.
FAQ ▾
What are BAKER BROS. ADVISORS LP's largest holdings?
As of the latest 13F: Incyte Genomics Inc 16.6%, Beone Medicines Ltd. 15.0%, Insmed, Inc. 7.0%, Madrigal Pharmaceuticals, Inc. Common Stock 6.4%, Acadia Pharmaceuticals Inc. 5.5%.
How big is BAKER BROS. ADVISORS LP's 13F portfolio?
$17.4B across 84 disclosed U.S.-equity positions.
What is BAKER BROS. ADVISORS LP's 3-year performance?
+92% (13F-replication, price return), +14 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.